DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fungizone (Amphotericin B) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

WARNING

This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis, and esophageal candidiasis in patients with normal neutrophil counts.

EXERCISE CAUTION to prevent inadvertent Fungizone overdose. Verify the product name and dosage if dose exceeds 1.5 mg/kg (see WARNINGS, OVERDOSAGE, and DOSAGE AND ADMINISTRATION).

 

FUNGIZONE SUMMARY

FUNGIZONE® INTRAVENOUS
Amphotericin B For Injection USP

FUNGIZONE intravenous (Amphotericin B for Injection) contains amphotericin B, an antifungal polyene antibiotic obtained from a strain of Streptomyces nodosus.

FUNGIZONE (amphotericin B) is indicated for the following:

FUNGIZONE Intravenous (Amphotericin B for Injection USP) should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts.

FUNGIZONE Intravenous is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis.

Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.


See all Fungizone indications & dosage >>

FUNGIZONE NEWS HIGHLIGHTS

Published Studies Related to Fungizone (Amphotericin B)

Postoperative application of amphotericin B nasal spray in chronic rhinosinusitis with nasal polyposis, with a review of the antifungal therapy. [2008.10.25]

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. [2008.10.15]

Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. [2008.10.07]

[Postoperative application of amphotericin B nasal spray in chronic rhinosinusitis with nasal polyposis. Can recidive polyposis be prevented?] [2008.09.14]

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. [2008.09]

more >>

Clinical Trials Related to Fungizone (Amphotericin B)

Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) [Completed]

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation [Completed]

A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar [Completed]

Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study [Completed]

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis [Terminated]

more >>

Page last updated: 2008-11-02

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008